Related coverage linked through entity extraction aliases.
Jul 27, 2026
FDA approved AstraZeneca's Breztri Aerosphere for asthma; EU CHMP recommended Trixeo. Phase 3 KALOS/LOGOS trials showed improved lung function and reduced severe exacerbations versus dual therapy.
Aug 06, 2026
Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
Apr 29, 2026
FDA approves AstraZeneca's Breztri Aerosphere as the first single-inhaler triple therapy for asthma in patients aged 12+, based on Phase III KALOS and LOGOS trials showing improved lung function and reduced exacerbations versus dual therapy.
Feb 28, 2026
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
Dec 30, 2025
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
Feb 13, 2026
Phase III KALOS and LOGOS trial results published in The Lancet Respiratory Medicine show Breztri Aerosphere improved lung function and reduced severe asthma exacerbations compared to dual-combination therapies in patients with uncontrolled asthma.
